COMMUNIQUÉS West-GlobeNewswire

Ardelyx Announces Changes to the Executive Leadership Team
04/08/2025
Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM, Mass [...]
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance
04/08/2025
Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, [...]
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
04/08/2025
-CASGEVY ® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong [...]
Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET
04/08/2025
HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will [...]
Cellectis publie ses résultats financiers du deuxième trimestre 2025 et une mise à jour de ses activités
04/08/2025
Cellectis organise un R&D Day dédié aux investisseurs à New York le 16 octobre 2025 : les données de phase 1 et la stratégie de développement de lasmé-cel (UCART22) dans la LAL-B r/r y seront présentés Les réunions [...]
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
04/08/2025
Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA [...]
Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)
04/08/2025
LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ ( [...]
Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease
04/08/2025
New whitepaper shows that a relationship with a primary care physician (“PCP”) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (“COPD”) diagnosis, increased [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2025
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
04/08/2025
MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of [...]
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04/08/2025
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it issued grants of employment inducement awards to [...]
Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results
04/08/2025
EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live [...]
Regional Health Properties, Inc. and SunLink Health Systems, Inc. Announce Receipt of Shareholder Approvals for Merger
04/08/2025
Atlanta, GA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCQB: RHEP) (OTCQB: RHEPA) and SunLink Health Systems, Inc. (“SunLink”) (NYSE American: SSY) jointly announced today that, [...]
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence
04/08/2025
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) reschedules its earnings release and conference call for the quarterly period ended June 30, [...]
iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market
05/08/2025
WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
05/08/2025
- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; " [...]
L’Avenue Derm: The Blueprint for Seven-Day Dermatologic Care, Revolutionizing Skin Health and Aesthetics
04/08/2025
L’Avenue Derm debuts in Manhattan with a one-month waitlist, redefining holistic dermatologic care. Members receive 7-day access to top dermatologists, yoga, nutrition, and tailored aesthetic treatments—seamlessly [...]
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
04/08/2025
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, announces it [...]
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
04/08/2025
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled [...]

Pages